Transplacental Aspirin Therapy for Early Onset Fetal Growth Restriction
Status:
Withdrawn
Trial end date:
2023-06-11
Target enrollment:
Participant gender:
Summary
The purpose of this investigation is to evaluate the ability of maternal aspirin (ASA)
therapy to prevent preterm birth for fetal indications prior to 32 weeks gestation in women
with early onset Fetal Growth Restriction (FGR). Aspirin is a commonly used medication that
blocks blood platelets from clumping. Aspirin crosses the placenta in a dose dependent mode.
There is preliminary evidence in smaller studies that aspirin can block fetal platelet
clumping and, therefore, slow down the progression of placental disease under specific
circumstances. The optimal time for aspirin to work is when the fetus' placental dysfunction
is still mild. The goal of this research study is to show if fetuses that receive aspirin
through maternal intake at a dose shown to affect fetal platelet aggregation will be less
likely to deliver before 32 weeks for fetal deterioration. The outcomes of patients that
receive aspirin will be compared to women that receive standard FGR management but do not
take any aspirin. The decision if a study participant receives aspirin or not will be
randomly picked. Such a research study is called a randomized controlled trial.